A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2070 Injection

NCT07241923 ↗

Phase 1 Recruiting 48 enrolled CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study of SYH2070 injection when administered subcutaneously to healthy subjects.

Timeline

Start: 2025-11-15
Primary completion: 2026-11-01
Completion: 2027-11-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SYH2070	Unknown	—	Subcutaneous

Indications

No indication recorded.